Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT versus ARISTOGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT versus ARISTOGEL.
ARISTOCORT vs ARISTOGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; modulates gene expression and immune cell activity.
Testosterone replacement therapy; binds to androgen receptors, activating gene transcription and increasing protein synthesis.
Intramuscular: 40-80 mg every 2-4 weeks; Intra-articular: 5-40 mg depending on joint size; Intralesional: 2.5-25 mg; Oral: 4-12 mg/day divided every 6-12 hours.
Aristogel is a topical gel containing 1% testosterone. The recommended adult dose is 5 g (50 mg testosterone) applied once daily to clean, dry, intact skin of shoulders, upper arms, and/or abdomen. Apply at approximately the same time each day, preferably in the morning.
None Documented
None Documented
Plasma: 1-2 hours (triamcinolone); tissue half-life 18-36 hours due to receptor binding and slow release from tissues.
Terminal elimination half-life is 12 hours. Given dosing frequency, steady-state achieved within 2 days; accumulation minimal with standard dosing.
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal elimination minor.
Primarily renal (80%) as unchanged drug; 20% fecal via biliary elimination.
Category C
Category C
Corticosteroid
Corticosteroid